JP2016510591A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016510591A5 JP2016510591A5 JP2015559038A JP2015559038A JP2016510591A5 JP 2016510591 A5 JP2016510591 A5 JP 2016510591A5 JP 2015559038 A JP2015559038 A JP 2015559038A JP 2015559038 A JP2015559038 A JP 2015559038A JP 2016510591 A5 JP2016510591 A5 JP 2016510591A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- mutation
- inhibitor
- detecting
- akt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000035772 mutation Effects 0.000 claims 15
- 201000011510 cancer Diseases 0.000 claims 14
- 210000004027 cells Anatomy 0.000 claims 8
- 239000003197 protein kinase b inhibitor Substances 0.000 claims 8
- 230000014509 gene expression Effects 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 5
- 101700006234 AKT1 Proteins 0.000 claims 4
- 102100001248 AKT1 Human genes 0.000 claims 4
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims 3
- 108040005185 1-phosphatidylinositol-3-kinase activity proteins Proteins 0.000 claims 3
- 101710031851 AKT1S1 Proteins 0.000 claims 3
- 102100017507 AKT1S1 Human genes 0.000 claims 3
- 101700006583 AKT2 Proteins 0.000 claims 3
- 101700004058 AKT3 Proteins 0.000 claims 3
- 102100006725 AKT3 Human genes 0.000 claims 3
- 108020004999 Messenger RNA Proteins 0.000 claims 3
- 229920002106 messenger RNA Polymers 0.000 claims 3
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims 2
- 108020004705 Codon Proteins 0.000 claims 2
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 claims 2
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims 2
- 230000003281 allosteric Effects 0.000 claims 2
- 230000003321 amplification Effects 0.000 claims 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims 2
- 230000002018 overexpression Effects 0.000 claims 2
- 230000001225 therapeutic Effects 0.000 claims 2
- YOVVNQKCSKSHKT-HNNXBMFYSA-N (2S)-1-[4-[[2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]piperazin-1-yl]-2-hydroxypropan-1-one Chemical compound C1CN(C(=O)[C@@H](O)C)CCN1CC1=C(C)C2=NC(C=3C=NC(N)=NC=3)=NC(N3CCOCC3)=C2S1 YOVVNQKCSKSHKT-HNNXBMFYSA-N 0.000 claims 1
- GRZXWCHAXNAUHY-NSISKUIASA-N (2S)-2-(4-chlorophenyl)-1-[4-[(5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-3-(propan-2-ylamino)propan-1-one Chemical group C1([C@H](C(=O)N2CCN(CC2)C=2C=3[C@H](C)C[C@@H](O)C=3N=CN=2)CNC(C)C)=CC=C(Cl)C=C1 GRZXWCHAXNAUHY-NSISKUIASA-N 0.000 claims 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical group C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 claims 1
- 101710042656 BQ2027_MB1231C Proteins 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010017758 Gastric cancer Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N Sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 230000002860 competitive Effects 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000002493 microarray Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 claims 1
- 238000003753 real-time PCR Methods 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
Claims (27)
- ＡＫＴ１又はＰＲＡＳ４０変異を含むがん細胞の変異の存在を検出することを含む、がん細胞におけるＡＫＴ阻害剤の治療効果に対する耐性を検出するための方法であって、変異の存在は、がん細胞がＡＫＴ阻害剤に耐性になったか又は耐性になるであろうことを示している、方法。
- 変異の存在が、ＡＫＴ阻害剤を用いた治療後に検出される、請求項１に記載の方法。
- ＡＫＴ１変異がＷ８０を含む、請求項１又は２に記載の方法。
- Ｗ８０変異がシステイン残基の変化を含む、請求項１から３の何れか一項に記載の方法。
- ＡＫＴ３の発現レベルを検出することを更に含む、請求項１から４の何れか一項に記載の方法。
- ＡＫＴ３の過剰発現を検出することを更に含む、請求項１から５の何れか一項に記載の方法。
- ＡＫＴ阻害剤がアロステリック阻害剤である、請求項１から６の何れか一項に記載の方法。
- アロステリック阻害剤がＭＫ−２２０６である、請求項１から７の何れか一項に記載の方法。
- ＰＲＡＳ４０変異が停止コドンを含む、請求項１又２に記載の方法。
- 変異が１７８停止コドンを含む、請求項１、２及び９の何れか一項に記載の方法。
- ＡＫＴ阻害剤がＡＴＰ競合的阻害剤である、請求項１、２、９及び１０の何れか一項に記載の方法。
- ＡＫＴ阻害剤がＧＤＣ−００６８又はＧＳＫ２１１０１８３である、請求項１、２及び９から１１の何れか一項に記載の方法。
- ＡＫＴ３発現レベルがｍＲＮＡ発現レベルである、請求項１から１２の何れか一項に記載の方法。
- ｍＲＮＡ発現レベルがマイクロアレイ又はｑＲＴ−ＰＣＲを用いて測定される、請求項１から１３の何れか一項に記載の方法。
- ｍＲＮＡ発現レベルの変化が増加である、請求項１から１４の何れか一項に記載の方法。
- がんが、中皮腫、子宮内膜がん、膵臓がん、乳がん、肺がん、卵巣がん、前立腺がん、黒色腫、胃がん、結腸がん、腎臓がん、頭頸部がん、及びグリオーマからなる群から選択される、請求項１から１５の何れか一項に記載の方法。
- がんがＰＴＥＮ変異と関連している、請求項１から１６の何れか一項に記載の方法。
- がんがＰＴＥＮが低いか又はゼロの状態と関連している、請求項１から１７の何れか一項に記載の方法。
- がんがＡＫＴ変異、過剰発現又は増幅と関連している、請求項１から１８に記載の方法。
- がんがＰＩ３Ｋ変異と関連している、請求項１から１９の何れか一項に記載の方法。
- がんがＨｅｒ２／ＥｒｂＢ２増幅と関連している、請求項１から２０の何れか一項に記載の方法。
- がん細胞が循環腫瘍細胞（ＣＴＣ）である、請求項１から２１の何れか一項に記載の方法。
- 検出がｐＣＲにより変異を検出することを更に含む、請求項１から２２の何れか一項に記載の方法。
- がん細胞におけるＡＫＴ阻害剤の治療効果に対する耐性を検出するためのキットであって、ＡＫＴ１又はＰＲＡＳ４０変異を含むがん細胞の変異の存在を検出するための手段を含み、変異の存在は、がん細胞がＡＫＴ阻害剤に耐性になったか又は耐性になるであろうことを示している、キット。
- がん細胞に、ＰＩ３Ｋ阻害剤又はｍＴＯＲ阻害剤の有効量が投与される、請求項２４に記載のキット。
- ＧＤＣ−０９４１及びＧＤＣ−０９８０から選択されるＰＩ３Ｋ阻害剤の有効量が投与される、請求項２４又は２５に記載のキット。
- ラパマイシンから選択されるｍＴＯＲ阻害剤の有効量が投与される、請求項２４又は２５に記載のキット。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361769108P | 2013-02-25 | 2013-02-25 | |
| US61/769,108 | 2013-02-25 | ||
| PCT/US2014/017948 WO2014130923A2 (en) | 2013-02-25 | 2014-02-24 | Methods and compositions for detecting and treating drug resistant akt mutant |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019088252A Division JP2019176858A (ja) | 2013-02-25 | 2019-05-08 | 薬物耐性ａｋｔ変異体を検出し治療するための方法及び組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016510591A JP2016510591A (ja) | 2016-04-11 |
| JP2016510591A5 true JP2016510591A5 (ja) | 2017-03-30 |
| JP6669500B2 JP6669500B2 (ja) | 2020-03-18 |
Family
ID=50290260
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015559038A Active JP6669500B2 (ja) | 2013-02-25 | 2014-02-24 | 薬物耐性ａｋｔ変異体を検出し治療するための方法及び組成物 |
| JP2019088252A Pending JP2019176858A (ja) | 2013-02-25 | 2019-05-08 | 薬物耐性ａｋｔ変異体を検出し治療するための方法及び組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019088252A Pending JP2019176858A (ja) | 2013-02-25 | 2019-05-08 | 薬物耐性ａｋｔ変異体を検出し治療するための方法及び組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9994913B2 (ja) |
| EP (1) | EP2959014B1 (ja) |
| JP (2) | JP6669500B2 (ja) |
| KR (1) | KR102182488B1 (ja) |
| CN (1) | CN105247072B (ja) |
| AR (1) | AR094873A1 (ja) |
| BR (1) | BR112015020054A2 (ja) |
| CA (1) | CA2901126C (ja) |
| MX (1) | MX369175B (ja) |
| RU (1) | RU2015140573A (ja) |
| WO (1) | WO2014130923A2 (ja) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2901126C (en) | 2013-02-25 | 2022-01-25 | Genentech, Inc. | Methods and compositions for detecting and treating drug resistant akt mutant |
| EP3162156B1 (en) | 2014-06-27 | 2020-04-22 | Techflux Inc. | Method and device for transmitting data unit |
| EP3380097A2 (en) * | 2015-08-28 | 2018-10-03 | Novartis AG | Pharmaceutical combination comprising (a) the alpha-isoform specific pi3k inhibitor alpelisib (byl719) and (b) an akt inhibitor, preferably mk-2206, afuresertib or uprosertib, and the use thereof in the treatment/prevention of cancer |
| WO2017078752A1 (en) * | 2015-11-06 | 2017-05-11 | The Penn State Research Foundation | Compositions and methods relating to cancer |
| CN112640031B (zh) * | 2018-08-13 | 2023-10-03 | 塞莫费雪科学（不来梅）有限公司 | 同位素质谱法 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1470356A1 (de) | 1964-01-15 | 1970-04-30 | Thomae Gmbh Dr K | Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| BE759493A (fr) | 1969-11-26 | 1971-05-25 | Thomae Gmbh Dr K | Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer |
| US3763156A (en) | 1970-01-28 | 1973-10-02 | Boehringer Sohn Ingelheim | 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines |
| RO62428A (fr) | 1971-05-04 | 1978-01-15 | Thomae Gmbh Dr K | Procede pour la preparation des thyeno-(3,2-d)-pyrimidines |
| US4018653A (en) | 1971-10-29 | 1977-04-19 | U.S. Packaging Corporation | Instrument for the detection of Neisseria gonorrhoeae without culture |
| IL47062A (en) | 1975-04-10 | 1979-07-25 | Yeda Res & Dev | Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde |
| US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| US4665077A (en) | 1979-03-19 | 1987-05-12 | The Upjohn Company | Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds |
| US4424279A (en) | 1982-08-12 | 1984-01-03 | Quidel | Rapid plunger immunoassay method and apparatus |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4683203A (en) | 1984-04-14 | 1987-07-28 | Redco N.V. | Immobilized enzymes, processes for preparing same, and use thereof |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US5583024A (en) | 1985-12-02 | 1996-12-10 | The Regents Of The University Of California | Recombinant expression of Coleoptera luciferase |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| IE61148B1 (en) | 1988-03-10 | 1994-10-05 | Ici Plc | Method of detecting nucleotide sequences |
| IL85746A (en) | 1988-03-15 | 1994-05-30 | Yeda Res & Dev | Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases |
| FI891226A (fi) | 1988-04-28 | 1989-10-29 | Univ Leland Stanford Junior | Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom. |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| WO1990008187A1 (en) | 1989-01-19 | 1990-07-26 | Dana Farber Cancer Institute | Soluble two domain cd2 protein |
| ES2062519T5 (es) | 1989-03-21 | 2003-07-16 | Immune Response Corp Inc | Vacunacion y metodos contra enfermedades originadas a partir de respuestas patogenicas mediante poblaciones especificas de linfocitos t. |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE69031919T3 (de) | 1989-07-19 | 2005-01-27 | Connetics Corp., Palo Alto | T-zell-rezeptor-peptide als heilmittel für autoimmune und bösartige krankheiten |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
| DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
| US5075305A (en) | 1991-03-18 | 1991-12-24 | Warner-Lambert Company | Compound, composition and use |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| ES2165851T3 (es) | 1991-11-25 | 2002-04-01 | Enzon Inc | Proteinas multivalentes que se unen a antigenos. |
| AU3262593A (en) | 1992-01-11 | 1993-08-03 | Schering Agrochemicals Limited | Biheterocyclic fungicidal compounds |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| JPH08336393A (ja) | 1995-04-13 | 1996-12-24 | Mitsubishi Chem Corp | 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法 |
| CA2761116A1 (en) | 1995-04-27 | 1996-10-31 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| WO1997045559A1 (en) | 1996-05-29 | 1997-12-04 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions |
| ATE549918T1 (de) | 1996-12-03 | 2012-04-15 | Amgen Fremont Inc | Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden |
| AUPO903897A0 (en) | 1997-09-08 | 1997-10-02 | Commonwealth Scientific And Industrial Research Organisation | Organic boronic acid derivatives |
| US6602677B1 (en) | 1997-09-19 | 2003-08-05 | Promega Corporation | Thermostable luciferases and methods of production |
| AU9454198A (en) | 1997-11-11 | 1999-05-31 | Pfizer Products Inc. | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
| AU760562B2 (en) | 1997-12-05 | 2003-05-15 | Scripps Research Institute, The | Humanization of murine antibody |
| US6187777B1 (en) | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
| ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| KR100940380B1 (ko) | 1999-01-15 | 2010-02-02 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| AU2001249727A1 (en) | 2000-03-31 | 2001-10-15 | Genentech, Inc. | Compositions and methods for detecting and quantifying gene expression |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| AU2001265121A1 (en) | 2000-05-30 | 2001-12-11 | Applera Corporation | Methods for detecting target nucleic acids using coupled ligation and amplification |
| US20030119004A1 (en) | 2001-12-05 | 2003-06-26 | Wenz H. Michael | Methods for quantitating nucleic acids using coupled ligation and amplification |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2005113762A1 (en) | 2004-05-18 | 2005-12-01 | Pfizer Products Inc. | CRYSTAL STRUCTURE OF PROTEIN KINASE B-α (AKT-1) AND USES THEREOF |
| GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| US8063050B2 (en) | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| WO2008049022A2 (en) * | 2006-10-18 | 2008-04-24 | Translational Genomics Research Institute | Methods for detection of cancer |
| WO2009006567A2 (en) | 2007-07-05 | 2009-01-08 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| EP2247756A2 (en) * | 2008-02-21 | 2010-11-10 | Université Libre de Bruxelles | Method and kit for the detection of genes associated with pik3ca mutation and involved in pi3k/akt pathway activation in the er-positive and her2-positive subtypes with clinical implications |
| EP2694073B1 (en) * | 2011-04-01 | 2018-08-08 | Genentech, Inc. | Combinations of akt and mek inhibitors for treating cancer |
| SG194050A1 (en) * | 2011-04-01 | 2013-11-29 | Genentech Inc | Biomarkers for predicting sensitivity to cancer treatments |
| WO2014089570A1 (en) * | 2012-12-07 | 2014-06-12 | The General Hospital Corporation | Combinations of a pi3k/akt inhibitor compound with an her3/egfr inhibitor compound and use thereof in the treatment of a hyperproliferative disorder |
| CA2901126C (en) | 2013-02-25 | 2022-01-25 | Genentech, Inc. | Methods and compositions for detecting and treating drug resistant akt mutant |
-
2014
- 2014-02-24 CA CA2901126A patent/CA2901126C/en active Active
- 2014-02-24 MX MX2015010776A patent/MX369175B/es active IP Right Grant
- 2014-02-24 AR ARP140100577A patent/AR094873A1/es active IP Right Grant
- 2014-02-24 RU RU2015140573A patent/RU2015140573A/ru not_active Application Discontinuation
- 2014-02-24 KR KR1020157026097A patent/KR102182488B1/ko active IP Right Grant
- 2014-02-24 WO PCT/US2014/017948 patent/WO2014130923A2/en active Application Filing
- 2014-02-24 CN CN201480023235.0A patent/CN105247072B/zh active Active
- 2014-02-24 BR BR112015020054A patent/BR112015020054A2/pt not_active Application Discontinuation
- 2014-02-24 JP JP2015559038A patent/JP6669500B2/ja active Active
- 2014-02-24 EP EP14711045.6A patent/EP2959014B1/en active Active
-
2015
- 2015-08-21 US US14/832,594 patent/US9994913B2/en active Active
-
2018
- 2018-05-08 US US15/974,533 patent/US10612100B2/en active Active
-
2019
- 2019-05-08 JP JP2019088252A patent/JP2019176858A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sexton et al. | Gastric cancer: a comprehensive review of current and future treatment strategies | |
| Newell et al. | Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo | |
| JP2016510591A5 (ja) | ||
| JP2016533366A5 (ja) | ||
| MY188938A (en) | Therapeutic, diagnostic and prognostic methods for cancer of the bladder | |
| Wang et al. | The role of microRNA in cisplatin resistance or sensitivity | |
| MX356802B (es) | Marcadores biologicos para identificar pacientes para tratamiento con antagonistas de vegf. | |
| WO2015052583A3 (en) | Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer | |
| WO2015172085A3 (en) | Biomarkers for response to pi3k inhibitors | |
| WO2014140933A3 (en) | Method for the prognosis and treatment of cancer metastasis | |
| WO2014036387A3 (en) | Methods for diagnosis and treatment of cancer | |
| WO2013182912A3 (en) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis | |
| EA201391805A1 (ru) | Молекулярно-диагностический тест на рак | |
| JP2017503481A5 (ja) | ||
| HRP20191145T1 (hr) | Postupak predviđanja ishoda liječenja s afliberceptom kod pacijenta za kojeg se sumnja da ima rak | |
| WO2014152777A3 (en) | Methods and compositions for the diagnosis and treatment of cancers resistant to ros1 inhibitors | |
| WO2013083098A3 (en) | Method of determination of cancer cell drug sensitivity towards aurora kinase inhibitors | |
| RU2015140573A (ru) | Способы и композиции для обнаружения и лечения устойчивого к лекарственным средствам мутанта акт | |
| WO2014057357A3 (en) | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf | |
| WO2016130572A3 (en) | Methods of determining levels of exposure to radiation and uses thereof | |
| Verbeke et al. | Active TGF-β signaling and decreased expression of PTEN separates angiosarcoma of bone from its soft tissue counterpart | |
| Zhu et al. | Systematic identification of dysregulated lncRNAs associated with platinum-based chemotherapy response across 11 cancer types | |
| EP3869198A3 (en) | Reagents and methods for breast cancer detection | |
| WO2014144451A3 (en) | Biomarkers for response to rapamycin analogs | |
| PH12020551980A1 (en) | Tumor marker, methylation detection reagent, kit and use thereof |